Trispecific Antibodies, AI Diagnostics, and Cancer Trials
Kilder
- Nature: Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial - Nature
- statnews.com: FDA revisits a rare cancer treatment it rejected a few months ago - statnews.com
- statnews.com: FDA to reconsider treatment for rare cancer after its surprise rejection - statnews.com
- biopharmadive.com: Angelini to buy Catalyst in $4B play for rare neuro drugs - BioPharma Dive
- bioworld.com: Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst - BioWorld News
- Biospace: PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients - BioSpace
- prnewswire.com: PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients - PR Newswire
- Labiotech: The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics - Labiotech.eu
- labiotech.eu: The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics - Labiotech.eu
- Fiercebiotech: Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics - Fierce Biotech
- fiercebiotech.com: Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics - Fierce Biotech
- wikimedia: Photo by Chairman of the Joint Chiefs of Staff from Washington D.C, United States / Wikimedia Commons / CC BY 2.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.